New York State Common Retirement Fund lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 202,988 shares of the biopharmaceutical company’s stock after selling 10,263 shares during the period. New York State Common Retirement Fund owned about 0.24% of Alnylam Pharmaceuticals worth $16,190,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after acquiring an additional 4,732,617 shares in the last quarter. Perceptive Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 831.4% in the first quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock worth $56,553,000 after acquiring an additional 985,000 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 305.0% in the second quarter. TIAA CREF Investment Management LLC now owns 508,852 shares of the biopharmaceutical company’s stock worth $40,586,000 after acquiring an additional 383,214 shares during the last quarter. Blue Ridge Capital L.L.C. increased its stake in shares of Alnylam Pharmaceuticals by 20.5% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,590,000 shares of the biopharmaceutical company’s stock worth $81,488,000 after acquiring an additional 270,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 3.7% in the first quarter. Vanguard Group Inc. now owns 5,660,213 shares of the biopharmaceutical company’s stock worth $290,086,000 after acquiring an additional 200,890 shares during the last quarter. 94.25% of the stock is owned by institutional investors.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the transaction, the president now owns 165,399 shares of the company’s stock, valued at $16,539,900. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 4.30% of the company’s stock.

A number of analysts recently issued reports on ALNY shares. Morgan Stanley reissued an “equal weight” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 10th. BidaskClub lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 16th. Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $85.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, September 20th. Chardan Capital reaffirmed a “buy” rating and set a $124.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, September 25th. Finally, Goldman Sachs Group, Inc. (The) raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $62.00 to $163.00 in a research note on Monday. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $98.63.

Shares of Alnylam Pharmaceuticals, Inc. (ALNY) opened at 122.31 on Tuesday. The stock has a 50 day moving average of $90.10 and a 200 day moving average of $73.29. The firm’s market cap is $11.22 billion. Alnylam Pharmaceuticals, Inc. has a 52 week low of $31.38 and a 52 week high of $125.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. During the same period in the previous year, the company posted ($1.05) earnings per share. The firm’s revenue for the quarter was up 82.9% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.19) earnings per share for the current year.

WARNING: “New York State Common Retirement Fund Decreases Holdings in Alnylam Pharmaceuticals, Inc. (ALNY)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/03/new-york-state-common-retirement-fund-decreases-holdings-in-alnylam-pharmaceuticals-inc-alny.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.